<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Intravenous Immunoglobulin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00028</strong>&#160; (BIOD00091, BTD00091)</td></tr><tr><th>Type</th><td>biotech</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Intravenous immunoglobulin (IVIg) is a mixture of IgG1 and other antibodies derived from healthy human plasma via Cohn fractionation. The purification process includes cold alcohol fractionation, polyethylene glycol precipitation, and ion exchange chromatography. IVIg contains the same distribution of IgG antibody subclasses as is found in the general human population. IgG subclasses are fully represented in the following proportions: 70.3% IgG1, 24.7% IgG2, 3.1% IgG3, and 1.9% IgG4. IVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders.</p></td></tr><tr><th>Protein structure</th><td><a href="/system/protein_structures/full/DB00028.png?1266600393"><img alt="Db00028" src="/system/protein_structures/thumb/DB00028.png?1266600393"></a></td></tr><tr><th>Protein chemical formula</th><td>C<sub>6332</sub>H<sub>9826</sub>N<sub>1692</sub>O<sub>1980</sub>S<sub>42</sub></td></tr><tr><th>Protein average weight</th><td>142682.3000</td></tr><tr><th>Sequences</th><td><pre class="sequence">&gt;IGG1
PSALTQPPSASGSLGQSVTISCTGTSSDVGGYNYVSWYQQHAGKAPKVIIYEVNKRPSGV
PDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYEGSDNFVFGTGTKVTVLGQPKANPTVT
LFPPSSEELQANKATEVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASS
YLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECSPLVLQESGPGLVKPSEALSLTCTV
SGDSINTILYYWSWIRQPPGKGLEWIGYIYYSGSTYGNPSLKSRVTISVNTSKNQFYSKL
SSVTAADTAVYYCARVPLVVNPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPQPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
KPSNTKVDKRVAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPQVKFNWYV
DGVQVHNAKTKPREQQYNSTYRVVSVLTVLHQNWLDGKEYKCKVSNKALPAPIEKTISKA
KGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD
SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL</pre><pre class="sequence">&gt;IgA2
ELVMTQSPSSLSASVGDRVNIACRASQGISSALAWYQQKPGKAPRLLIYDASNLESGVPS
RFSGSGSGTDFTLTISSLQPEDFAIYYCQQFNSYPLTFGGGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECQVKLLEQSGAEVKKPGASVKVSCKAS
GYSFTSYGLHWVRQAPGQRLEWMGWISAGTGNTKYSQKFRGRVTFTRDTSATTAYMGLSS
LRPEDTAVYYCARDPYGGGKSEFDYWGQGTLVTVSSASPTSPKVFPLSLDSTPQDGNVVV
ACLVQGFFPQEPLSVTWSESGQNVTARNFPPSQDASGDLYTTSSQLTLPATQCPDGKSVT
CHVKHYTNPSQDVTVPCPVPPPPPCCHPRLSLHRPALEDLLLGSEANLTCTLTGLRDASG
ATFTWTPSSGKSAVQGPPERDLCGCYSVSSVLPGCAQPWNHGETFTCTAAHPELKTPLTA
NITKSGNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYL
TWASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRLAGKPT
HVNVSVVMAEVDGTCY</pre><small><a class="btn btn-info btn-sm" href="/drugs/DB00028/polypeptide_sequences.fasta">Download FASTA Format</a></small></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Ig alpha-2 chain C region</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>immune globulin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Immunoglobulin G</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Civacir</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Flebogamma</td><td>Instituto Grifols SA</td></tr><tr><td>Gamunex</td><td>Talecris Biotherapeutics</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/immunologic-factors">Immunologic Factors</a></li>
<li><a href="/mesh/immunosuppressive-agents">Immunosuppressive Agents</a></li>
<li><a href="/mesh/anti-infective-agents">Anti-Infective Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>9007-83-4</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>IVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders. These indications includes idiopathic thrombocytopenic purpura, Kawasaki disease, hypogammaglobulinemia, B cell chronic lymphocytic leukemia, bone marrow transplant complications, Guillain-Barr&#233; syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), multiple sclerosis, rheumatoid arthritis, myesthenia gravis, Wiskott&#8211;Aldrich syndrome and inflammatory skin diseases.</td></tr><tr><th>Pharmacodynamics</th><td>Used as a replacement therapy in inherited humoral immunodeficiency disorders such as severe combined immunodeficiency syndrome, x-linked agammaglobulinemia, and Wiskott-Aldrich Syndrome. The immunoglobulins target, bind and kill bacterial cells as well as viral particles. IgG is the monomeric immunoglobulin of which there are four subclasses (IgG1, IgG2, IgG3 and IgG4) in differing abundances (66%, 23%, 7% and 4%). IgAs represent about 15% of the immunoglobulins in the blood. These target inhaled or ingested pathogens.</td></tr><tr><th>Mechanism of action</th><td>IVIg interacts with a number of different components of the immune system, including cytokines, complement, Fc receptors and several cell surface immunocompetent molecules. IVIg also impacts different effector cells of the immune system (B and T lymphocytes, dendritic cells, etc.) and regulates a wide range of genes. Its main mechanism of actions are believed to be Fc-dependent and F(ab')2-dependent. IVIg competitively blocks gamma Fc receptors, preventing the binding and ingestion of phagocytes and suppressing platelet depletion. IVIg contains a number of different antobodies, which prevent infection by attaching to the surface of invading pathogens and aiding in their disposal before they can infect cells. Antibodies remove pathogens via complement activation, agglutination or precipitation, pathogen receptor blocking, macrophage &#8220;tagging&#8221; or neutralization (via binding) of pathogen toxins. Intact IVIg and F(ab&#8242;)2 fragments of IVIg can also neutralize the activity of various autoantibodies. By triggering the production of interleukin-1 receptor antagonist, IVIg modulates of the production of cytokines and cytokine antagonists. It also prevents the generation of the C5b-9 membrane attack complex and subsequent complement-mediated tissue damage by binding active complement components.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>&gt;20 hours (mammalian reticulocytes, in vitro).</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li>
<li>Bacteria and protozoa</li>
<li>Various viruses</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><ul><li>Alpha Therapeutic Corp.</li>
<li><a href="http://www.redcross.org">American Red Cross</a></li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.biotestpharma.com">Biotest Pharmaceuticals</a></li>
<li><a href="http://www.cangene.com">Cangene Corp.</a></li>
<li><a href="http://www.cslbehring.com">CSL Behring LLC</a></li>
<li><a href="http://www.grifols.com">Grifols SA</a></li>
<li><a href="http://www.mphaweb.org">Massachusetts Public Health</a></li>
<li><a href="http://www.massbio.org">Massbiologics</a></li>
<li><a href="http://www.medimmune.com">Medimmune Inc.</a></li>
<li><a href="http://www.novartis.com">Novartis AG</a></li>
<li><a href="http://www.octapharma.com">Octapharma USA</a></li>
<li><a href="http://www.talecris.com">Talecris Biotherapeutics</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Powder, for solution</td><td>Intravenous</td><td></td></tr><tr><td>Solution</td><td>Intramuscular</td><td></td></tr><tr><td>Solution</td><td>Intravenous</td><td></td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Hypertet s-d 250 unit syringe</td><td>324.23USD</td><td>syringe</td></tr><tr><td>Hyperrab s-d vial</td><td>224.07USD</td><td>ml</td></tr><tr><td>Nabi-hb vial</td><td>176.34USD</td><td>ml</td></tr><tr><td>Hyperhep b s-d vial</td><td>165.04USD</td><td>ml</td></tr><tr><td>Hizentra 1 gram/5 ml vial</td><td>30.24USD</td><td>ml</td></tr><tr><td>Hizentra 2 gram/10 ml vial</td><td>30.24USD</td><td>ml</td></tr><tr><td>Hizentra 4 gram/20 ml vial</td><td>30.24USD</td><td>ml</td></tr><tr><td>Gamastan s-d vial</td><td>24.44USD</td><td>ml</td></tr><tr><td>Gammagard liquid 10% vial</td><td>13.79USD</td><td>ml</td></tr><tr><td>Gamunex 10% vial</td><td>11.6USD</td><td>ml</td></tr><tr><td>Immune globulin vial</td><td>9.34USD</td><td>ml</td></tr><tr><td>Flebogamma 5% vial</td><td>4.84USD</td><td>ml</td></tr><tr><td>Flebogamma dif 5% vial</td><td>4.84USD</td><td>ml</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>liquid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>61 &#176;C (FAB fragment), 71 &#176;C (whole mAb)</td><td>Vermeer, A.W.P. &amp; Norde, W., Biophys. J. 78:394-404 (2000)</td></tr><tr><td>hydrophobicity</td><td>-0.331</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>isoelectric point</td><td>8.13</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Wolfgang Stephan, &#8220;Production of intravenously applicable native human immune globulin having a normal half-life.&#8221; U.S. Patent US4082734, issued July, 1970.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=4082734&amp;tbm=pts" target="_blank">US4082734 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Bayry J, Fournier EM, Maddur MS, Vani J, Wootla B, Siberil S, Dimitrov JD, Lacroix-Desmazes S, Berdah M, Crabol Y, Oksenhendler E, Levy Y, Mouthon L, Sautes-Fridman C, Hermine O, Kaveri SV: Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun. 2011 Feb;36(1):9-15. Epub 2010 Dec 9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20970960">Pubmed</a></li>
	<li>Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17911465">Pubmed</a></li>
	<li>Stangel M, Pul R: Basic principles of intravenous immunoglobulin (IVIg) treatment. J Neurol. 2006 Sep;253 Suppl 5:V18-24. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16998749">Pubmed</a></li>
	<li>Emmi L, Chiarini F: The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders. Neurol Sci. 2002 Apr;23 Suppl 1:S1-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12032582">Pubmed</a></li>
	<li>http://www.path.cam.ac.uk/~mrc7/lecturenotes/handout1a.pdf</li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>UniProt</td><td><a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P01877" target="_blank">P01877 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Genbank</td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=J00221" target="_blank">J00221 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA164754884" target="_blank">PA164754884 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2230920" target="_blank">2230920 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic2/baygam.htm" target="_blank">http://www.rxlist.com/cgi/generic2/baygam.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/immune-globulin-human.html" target="_blank">http://www.drugs.com/cdi/immune-globulin-human.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>J06BA02<ul class="atc-drug-tree"><li><a href="/atc/J#J">J &#8212; ANTIINFECTIVES FOR SYSTEMIC USE</a></li><li><a href="/atc/J06#J06">J06 &#8212; IMMUNE SERA AND IMMUNOGLOBULINS</a></li><li><a href="/atc/J06B#J06B">J06B &#8212; IMMUNOGLOBULINS</a></li><li><a href="/atc/J06BA#J06BA">J06BA &#8212; Immunoglobulins, normal human</a></li></ul>J06BA01<ul class="atc-drug-tree"><li><a href="/atc/J#J">J &#8212; ANTIINFECTIVES FOR SYSTEMIC USE</a></li><li><a href="/atc/J06#J06">J06 &#8212; IMMUNE SERA AND IMMUNOGLOBULINS</a></li><li><a href="/atc/J06B#J06B">J06B &#8212; IMMUNOGLOBULINS</a></li><li><a href="/atc/J06BA#J06BA">J06BA &#8212; Immunoglobulins, normal human</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>80:04.00</li></ul></td></tr><tr><th>PDB Entries</th><td><ul><li><a class="wishart-link-out" href="http://www.rcsb.org/pdb/explore.do?structureId=1IGT" target="_blank">1IGT <span class="glyphicon glyphicon-new-window"> </span></a></li></ul></td></tr><tr><th>FDA label</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>MSDS</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>